Neurocrine Biosciences Launches Phase I Trial of GLP-1/GIP/Glucagon Triple Agonist NBIP-1968 for Obesity
核心洞察
Neurocrine Biosciences has dosed the first participants in a Phase I first-in-human study of NBIP-1968 (搜索), an investigational GLP-1 (搜索)/GIP (搜索)/glucagon receptor triple agonist for obesity (搜索).
The study will evaluate safety and tolerability of single ascending doses in adults across a range of body mass index categories, including overweight and obese.
NBIP-1968 (搜索) is designed for once-weekly subcutaneous administration and is intended for use in a fixed-dose combination with NBIP-2118 (搜索), a CRF2 (搜索) agonist aimed at preserving lean mass during weight loss.
Neurocrine Biosciences has dosed the first participants in a Phase I first-in-human clinical study of NBIP-1968 (搜索), an internally discovered GLP-1 (搜索)/GIP (搜索)/glucagon receptor triple agonist being developed as a therapy for obesity (搜索). The announcement, made on August 7, 2026, marks a significant milestone in the company's strategic expansion from its established neuroscience and endocrinology portfolio into the metabolic disease space.
The Phase I study will evaluate the safety and tolerability of single ascending doses of NBIP-1968 (搜索) in adult participants across a range of body mass index categories, including overweight and obese individuals. Safety and tolerability serve as the primary endpoint. No efficacy or safety data have been reported, and the company has not disclosed a timeline for when initial data will be available.
Mechanism and Rationale
NBIP-1968 (搜索) is designed for once-weekly subcutaneous administration and targets three receptors simultaneously: glucagon-like peptide-1 (GLP-1 (搜索)), glucose-dependent insulinotropic polypeptide (GIP (搜索)), and glucagon. By engaging all three receptors, the molecule aims to influence metabolic pathways involved in appetite regulation, energy balance, and glycemic control.
According to Neurocrine, the molecule was engineered with balanced glucagon receptor activity — an approach intended to capture the metabolic benefits of glucagon agonism, including increased energy expenditure, while managing the tolerability concerns that have complicated earlier glucagon-containing combination therapies.
"Obesity (搜索) is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer at Neurocrine Biosciences. "NBIP-1968 (搜索) is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity."
A Broader Combination Strategy
The trial's strategic significance extends beyond NBIP-1968 (搜索) as a standalone candidate. Neurocrine intends for NBIP-1968 to serve as one component of a fixed-dose combination with NBIP-2118 (搜索), a corticotropin-releasing factor type 2 receptor (CRF2 (搜索)) agonist that entered Phase I testing in May 2026. NBIP-2118 targets a non-incretin mechanism and has demonstrated fat-preferential weight loss with lean mass preservation in preclinical models.
This combination strategy — pairing incretin-based weight loss with a muscle-sparing mechanism — reflects an effort to address one of the recognized limitations of current GLP-1 (搜索)-class therapies, which reduce lean mass alongside fat mass. Jude Onyia, Ph.D., Chief Scientific Officer at Neurocrine, stated: "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity (搜索)."
Initial data from the NBIP-2118 (搜索) Phase I study are expected in 2027. Neurocrine's broader obesity (搜索) research pipeline also includes a single-molecule incretin mimetic-CRF2 (搜索) agonist conjugate and a long-acting triple agonist conjugated to an antibody Fc domain intended to extend the dosing interval to once monthly or less frequently.
Competitive Landscape
The obesity (搜索) pharmacotherapy market has undergone rapid transformation. Eli Lilly's Zepbound (tirzepatide), a dual GIP (搜索)/GLP-1 (搜索) receptor agonist, and Novo Nordisk's Wegovy (semaglutide 2.4 mg) currently anchor the injectable market, with tirzepatide demonstrating the highest mean weight loss of any approved agent. Eli Lilly's Foundayo (orforglipron), the first oral non-peptide GLP-1 receptor agonist approved for obesity, received FDA approval in April 2026, further intensifying competition.
Adding a glucagon receptor component to GLP-1 (搜索)/GIP (搜索) agonism is a mechanism several developers have pursued as a potential route to greater weight loss, though clinical validation of the triple agonist approach in obesity (搜索) remains limited. Neurocrine's entry into this space draws on the company's existing expertise in CRF biology — the same pathway underpinning NBIP-2118 (搜索).
Disease Context
Obesity (搜索) is a chronic disease associated with serious health conditions including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, certain cancers, and osteoarthritis. Despite recent therapeutic advances, Neurocrine notes that current therapies can present challenges related to gastrointestinal tolerability, dose titration, and muscle loss, underscoring the rationale for pursuing differentiated mechanisms.